Biohaven Ltd.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$745.4 | -$885.1 | -$436.1 | -$567.9 | -$218.9 |
| Net income | -$738.8 | -$846.4 | -$408.2 | -$570.3 | -$213.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$610.2 | -$586.5 | -$334.8 | -$303.8 | -$146.8 |
Shares outstanding 151.0M · Free float 99.9%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 27, 2026
Deals
Biohaven to Buy SK Biopharm's Kv7 Assets in $795 Million Deal
July 22, 2026
Passive Ownership Watch
Passive Ownership Shifts in Index Holdings